Recent Updates
Recently added Catalysts
ENOV Positive Sentiment Score: 85/100

Enovis Completes Acquisition of LimaCorporate S.p.A WILMINGTON, DE

Key Takeaway: Enovis Corporation has completed its acquisition of LimaCorporate S.p.A., strengthening its position in the global orthopedic reconstruction market. Lima brings a proven surgical solutions portfolio, including 3D printed Trabecular Titanium implants, enhancing Enovis' capabilities in the extremities market. This acquisition is expected to accelerate growth and increase revenue, bringing Enovis' reconstruction segment revenues to $1 billion. The integration of Lima's team is viewed as a strategic move to drive long-term value for shareholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Acquisition enhances Enovis' position in the orthopedic reconstruction market.
  • Lima's innovative portfolio includes advanced 3D printed implants.
  • Expected to accelerate global growth and expansion of margins.
  • Combines revenues to reach $1 billion in the reconstruction segment.

Full Press Release Details

Enovis Completes Acquisition of LimaCorporate S.p.A
WILMINGTON, DE, January 3, 2024 (GLOBE NEWSWIRE) Enovis Corporation (NYSE: ENOV,
Enovis or the Company ) an innovation-driven, medical technology growth company, today announced that it closed the acquisition of LimaCorporate S.p.A. ( Lima ), a privately held global orthopedic leader
focused on restoring motion through an innovative portfolio of implant solutions.
Lima strengthens Enovis position in the global
orthopedic reconstruction market with a complementary portfolio of proven surgical solutions and technologies, which will accelerate global growth and margin expansion. In addition, Lima s portfolio includes 3D printed Trabecular Titanium
implants and a comprehensive revision offering in shoulders, which will further strengthen the Company s position in the fast-growing extremities market.
We are excited to welcome Lima s talented team to Enovis. The combination brings Enovis recon segment to $1 billion in revenues and
creates a fast-growing innovator in the global orthopedic reconstruction market. This is another great example of how we use strategic acquisitions to accelerate our growth, add great technologies and talent to our company, and drive compounding
value for our shareholders, said Matt Trerotola, Chair, and Chief Executive Officer of Enovis.
About Enovis Corporation
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that
generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent, and innovation, the Company s extensive range of products, services, and integrated technologies fuels active
lifestyles in orthopedics and beyond. The Company s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For additional information about Enovis, please visit www.enovis.com.
Forward-Looking Statements
includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the
Company s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on the Company s current expectations and involve risks and uncertainties that
could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause the Company s results to differ materially from current expectations include, but are not limited to,
risks and uncertainties regarding the Company s and Lima s respective businesses, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the effects of the acquisition on the Company s
and Lima s operations, including on the combined company s future financial condition and performance, operating results, strategy and plans, including anticipated tax treatment, unforeseen liabilities, future capital expenditures,
revenues, expenses, earnings, synergies, economic performance, indebtedness, losses, future prospects, and business and management strategies for the management, expansion and growth of the new combined company s operations; the potential
the consummation of the acquisition on relationships with customers, suppliers and other third parties; and the other factors detailed in the Company s reports filed with the U.S. Securities
and Exchange Commission (the SEC ), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on
Form 10-Q under the caption Risk Factors, as well as the other risks discussed in the Company s filings with the SEC. In addition, these statements are based on assumptions that are
subject to change. This press release speaks only as of the date hereof. The Company disclaims any duty to update the information herein.
Vice President, Investor
Vice President, Corporate Communications

Frequently Asked Questions

What is the recent acquisition completed by Enovis?

Enovis has completed the acquisition of LimaCorporate S.p.A., enhancing its orthopedic offerings.

How does LimaCorporate enhance Enovis's position?

Lima's innovative implant solutions complement Enovis's portfolio, boosting growth and market position.

What is the expected revenue impact of this acquisition?

The acquisition will bring Enovis's reconstruction segment to $1 billion in revenues.

What technologies are included in Lima's portfolio?

Lima's portfolio features 3D printed Trabecular Titanium implants and shoulder revision offerings.

Where can I find more information about Enovis?

Further details can be found on Enovis's website at www.enovis.com.

Last updated: Jan 3, 2024